Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of polyclonal antibodies, developed in Japan by AnGes MG using Vical's DNA vaccine technology, for the treatment of Ebola virus infection

Trial Profile

Phase I trial of polyclonal antibodies, developed in Japan by AnGes MG using Vical's DNA vaccine technology, for the treatment of Ebola virus infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Polyclonal antibodies (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors AnGes
  • Most Recent Events

    • 30 Jan 2015 New trial record
    • 14 Jan 2015 AnGes has signed an agreement with Vical for the rights to develop and commercialise this product in Japan, and this trial is expected to be initiated in the first quarter of 2015, according to an AnGes MG media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top